AMRI and Knopp Biosciences LLC have entered into a strategic agreement, under which AMRI will provide discovery-related services including medicinal chemistry, DMPK and computer-aided drug discovery (CADD). AMRI scientists will also collaborate with Knopp on selected drug discovery programs. Upon mutual agreement, the collaboration may be extended after two years.
 
"We are pleased to expand our relationship with Knopp Biosciences, a company that values innovation through collaboration," said AMRI's chairman, president and chief executive officer, Thomas E. D'Ambra, Ph.D. "This agreement will combine AMRI's broad range of drug discovery capabilities, with more than 20 years of CNS experience, to assist Knopp in its goal of delivering safe and effective treatments for unmet medical need."